FDA advisory committee recommends approval for Pfizer's Sutent

NEW YORK — A Food and Drug Administration expert panel has given a favorable vote to a drug made by Pfizer for tumors, Pfizer said Tuesday.

The FDA’s Oncologic Drugs Advisory Committee voted 8-2 that Sutent’s (sunitinib malate) benefits outweigh its risks in the treatment of unresectable pancreatic neuroendocrine tumors.

While the FDA is not bound by advisory committee votes, it takes them into consideration when deciding whether or not to approve a drug.